Report cover image

South Korea Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging center

Publisher Allied Market Research
Published May 02, 2023
Length 79 Pages
SKU # ALMR18790700

Description

South Korea Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032


The radiopharmaceutical industry has seen substantial development over the previous years, particularly with technical advancements in the medical market that enable much better medical diagnosis as well as treatments of different conditions. South Korea radiopharmaceuticals market has also observed a growing demand, as the medical sector in the country develops as well as adopts brand-new innovation. Radiopharmaceuticals medications that are radioactively classified and used in the medical diagnosis as well as treatment of various diseases.

The South Korea radiopharmaceuticals market is being driven by the increasing demand for more advanced analysis as well as therapeutic procedures, due to the growing occurrence of illnesses such as cancer in the nation. The increasing number of cancer cases has required using innovative diagnostic and restorative therapies, and radiopharmaceuticals provide both. On top of that, the advancement of radiopharmaceuticals for the diagnosis and treatment of conditions besides cancer, such as muscular dystrophy, is driving further development.

A significant factor driving the market for radiopharmaceuticals is the alarming rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological diseases. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease. Around 1.9 million new cancer cases were estimated to have been identified in the United States in 2022, according to American cancer Society. In addition, the National Cancer Institute reported that around 50% of all cancer patients are prescribed radiation therapy at some point during their treatment.

On the other hand, the South Korea radiopharmaceuticals market is encountering restrictions because of the high expense of radiopharmaceuticals and the shortage of isotopes used to produce them. The high expense of radiopharmaceuticals is a result of the strict regulations laid to handle and manufacture them. Isotope shortages are also a factor, as most of the isotopes needed for production are sourced from abroad, hence subject to international market pressures.

There are many opportunities for further development on the South Korea radiopharmaceutical market, but there are also some limitations. The aging population in South Korea is a significant element driving the development of the radiopharmaceuticals market. The increasing age of the populace results in an expanding number of people needing development treatments for various diseases, including cancer.

Additionally, increasing research and development activity in the country is creating new as well as better radiopharmaceuticals which can be used for much more accurate medical diagnoses as well as therapies. This is encouraging a lot more players to enter the market. All of these aspects together are expected to drive the growth of the South Korea radiopharmaceuticals market over the coming years. The South Korea radiopharmaceutical industry now has lot of scope to grow as result of recent advances in radiopharmaceuticals. More accurate diagnosis and treatments are now possible thanks to technological advancements, which are also creating a potential for novel radiopharmaceuticals.

The radiopharmaceuticals market is segmented on the basis of radioisotope (technetium 99m, fluorine 18, iodine I, gallium 68, and others), by application (cancer, cardiology, and others), by type (diagnostic and therapeutic), and by end user (hospitals & clinics, medical imaging facilities, and others). Technetium 99m is the most extensively used radioisotope in the South Korea radiopharmaceuticals market, followed by fluorine 18 and gallium 68. The radiopharmaceuticals market is largely driven by the high prevalence of different cancers in the country as well as the expanding demand from health centers as well as facilities for better analysis and therapies.

The South Korea radiopharmaceuticals market offers numerous qualitative insights on the growth of the market, such as R&D. Businesses in the market are actively engaged in R & D activities to create more breakthrough radiopharmaceuticals to satisfy the growing need for therapies. In addition, companies are also looking to make their products inexpensive and accessible. Consumer or end user awareness is likewise essential in the South Korean radiopharmaceuticals market. The increasing awareness of using radiopharmaceuticals in the nation is driving the demand and creating more opportunities for businesses in the market.

The South Korea radiopharmaceuticals market is poised for solid development in the upcoming years. According to Porter's five forces analysis, the intensity of rivalry among market players in the South Korea radiopharmaceuticals market is medium, as there are major players who have a solid hold on the market. The bargaining power of buyers is low, as the radiopharmaceuticals industry is still growing and there are not nearly enough choices available to the clients.

Samsung Biologics, Daewoong Pharmaceutical, Chong Kun Dang Pharmaceutical, Dong-A ST, G.HOUSE Pharma, Yuhan Corporation, Hanlim Pharm, Chemo-Sero-Therapeutic Research Institute, Genexine, Celltrion Healthcare are some of the companies operating in the market.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in South Korea radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of South Korea radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the South Korea radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Diagnostic
Therapeutic

By End User

Hospitals and clinics
Medical Imaging centers
Others

By Radioisotope

Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m

By Application

Cancer
Cardiology
Others

Key Market Players

Samsung Biologics
Daewoong Pharmaceutical
Chong Kun Dang Pharmaceutical
Dong-A ST
G.HOUSE Pharma
Yuhan Corporation
Hanlim Pharm
Chemo-Sero-Therapeutic Research Institute
Genexine
Celltrion Healthcare

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

79 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Samsung Biologics
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Daewoong Pharmaceutical
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Chong Kun Dang Pharmaceutical
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Dong-A ST
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. G.HOUSE Pharma
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Yuhan Corporation
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Hanlim Pharm
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Chemo-Sero-Therapeutic Research Institute
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Genexine
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Celltrion Healthcare
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. SAMSUNG BIOLOGICS: KEY EXECUTIVES
TABLE 06. SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
TABLE 07. SAMSUNG BIOLOGICS: OPERATING SEGMENTS
TABLE 08. SAMSUNG BIOLOGICS: PRODUCT PORTFOLIO
TABLE 09. SAMSUNG BIOLOGICS: KEY STRATERGIES
TABLE 10. DAEWOONG PHARMACEUTICAL: KEY EXECUTIVES
TABLE 11. DAEWOONG PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 12. DAEWOONG PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 13. DAEWOONG PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 14. DAEWOONG PHARMACEUTICAL: KEY STRATERGIES
TABLE 15. CHONG KUN DANG PHARMACEUTICAL: KEY EXECUTIVES
TABLE 16. CHONG KUN DANG PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 17. CHONG KUN DANG PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 18. CHONG KUN DANG PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 19. CHONG KUN DANG PHARMACEUTICAL: KEY STRATERGIES
TABLE 20. DONG-A ST: KEY EXECUTIVES
TABLE 21. DONG-A ST: COMPANY SNAPSHOT
TABLE 22. DONG-A ST: OPERATING SEGMENTS
TABLE 23. DONG-A ST: PRODUCT PORTFOLIO
TABLE 24. DONG-A ST: KEY STRATERGIES
TABLE 25. G.HOUSE PHARMA: KEY EXECUTIVES
TABLE 26. G.HOUSE PHARMA: COMPANY SNAPSHOT
TABLE 27. G.HOUSE PHARMA: OPERATING SEGMENTS
TABLE 28. G.HOUSE PHARMA: PRODUCT PORTFOLIO
TABLE 29. G.HOUSE PHARMA: KEY STRATERGIES
TABLE 30. YUHAN CORPORATION: KEY EXECUTIVES
TABLE 31. YUHAN CORPORATION: COMPANY SNAPSHOT
TABLE 32. YUHAN CORPORATION: OPERATING SEGMENTS
TABLE 33. YUHAN CORPORATION: PRODUCT PORTFOLIO
TABLE 34. YUHAN CORPORATION: KEY STRATERGIES
TABLE 35. HANLIM PHARM: KEY EXECUTIVES
TABLE 36. HANLIM PHARM: COMPANY SNAPSHOT
TABLE 37. HANLIM PHARM: OPERATING SEGMENTS
TABLE 38. HANLIM PHARM: PRODUCT PORTFOLIO
TABLE 39. HANLIM PHARM: KEY STRATERGIES
TABLE 40. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: KEY EXECUTIVES
TABLE 41. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: COMPANY SNAPSHOT
TABLE 42. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: OPERATING SEGMENTS
TABLE 43. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: PRODUCT PORTFOLIO
TABLE 44. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: KEY STRATERGIES
TABLE 45. GENEXINE: KEY EXECUTIVES
TABLE 46. GENEXINE: COMPANY SNAPSHOT
TABLE 47. GENEXINE: OPERATING SEGMENTS
TABLE 48. GENEXINE: PRODUCT PORTFOLIO
TABLE 49. GENEXINE: KEY STRATERGIES
TABLE 50. CELLTRION HEALTHCARE: KEY EXECUTIVES
TABLE 51. CELLTRION HEALTHCARE: COMPANY SNAPSHOT
TABLE 52. CELLTRION HEALTHCARE: OPERATING SEGMENTS
TABLE 53. CELLTRION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 54. CELLTRION HEALTHCARE: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SOUTH KOREA RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SOUTH KOREA RADIOPHARMACEUTICALS MARKET
FIGURE 10. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: SOUTH KOREA RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. SAMSUNG BIOLOGICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 22. SAMSUNG BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. SAMSUNG BIOLOGICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. DAEWOONG PHARMACEUTICAL: NET SALES, 2020-2022* ($MILLION)
FIGURE 25. DAEWOONG PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. DAEWOONG PHARMACEUTICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. CHONG KUN DANG PHARMACEUTICAL: NET SALES, 2020-2022* ($MILLION)
FIGURE 28. CHONG KUN DANG PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. CHONG KUN DANG PHARMACEUTICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. DONG-A ST: NET SALES, 2020-2022* ($MILLION)
FIGURE 31. DONG-A ST: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. DONG-A ST: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. G.HOUSE PHARMA: NET SALES, 2020-2022* ($MILLION)
FIGURE 34. G.HOUSE PHARMA: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. G.HOUSE PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. YUHAN CORPORATION: NET SALES, 2020-2022* ($MILLION)
FIGURE 37. YUHAN CORPORATION: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. YUHAN CORPORATION: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. HANLIM PHARM: NET SALES, 2020-2022* ($MILLION)
FIGURE 40. HANLIM PHARM: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. HANLIM PHARM: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: NET SALES, 2020-2022* ($MILLION)
FIGURE 43. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. GENEXINE: NET SALES, 2020-2022* ($MILLION)
FIGURE 46. GENEXINE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. GENEXINE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. CELLTRION HEALTHCARE: NET SALES, 2020-2022* ($MILLION)
FIGURE 49. CELLTRION HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. CELLTRION HEALTHCARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us